Drug Database
Back to search

Netherlands· NL-5bc9556fcd2e

Lacidipine Double-e Pharma 6 mg filmomhulde tabletten

A lacidipine product containing lacidipine, registered in Netherlands by Double-E Pharma Ltd.. The same ATC class is registered in 7 of our 19 countries.

ATC C08CA09

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLacidipine Double-e Pharma 6 mg filmo…ATCC08CA09REGISTER NO.NL-5bc9556fcd2ePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lacidipineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lacidipine is registered in 7 of 19 countries.

Countries holding a registration under ATC C08CA09 (lacidipine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 4 of them publish a price we can compare per daily dose
Search lacidipine products by name

Lacidipine · ATC C08CA09

7 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Italyprice
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of lacidipine costs, country by country.

Normalised to the WHO defined daily dose (4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Lacidipine · price per daily dose (4 mg)

USD · FX 28 Sept 2026

  • IT Italy$0.37
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LACIDIPINE
Manufacturer
Double-E Pharma Ltd.
Country
Netherlands (NL)
ATC code
C08CA09
ATC class
Lacidipine
Defined daily dose
4 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    114065

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for lacidipine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lacidipine against other medicinesHow interaction checks work

Lacidipine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lacidipine in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lacidipine products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Bulgaria · Ласипил
  • Czechia · Lacipil
  • Denmark · Lacidipin Teva
  • Estonia · Lacipil, Prelum
  • Spain · Lacidipino Teva, Lacimen
  • United Kingdom (Northern Ireland) · Lacidipine Dr. Reddy's Laboratories (Uk), Lacidipine Generics [uk] Ltd
  • Greece · Lacipil
  • Croatia · Lacidipin Belupo, Lacipil
  • Hungary · Lacipil
  • Italy · Aponil, Lacidipina Doc Generici
  • Lithuania · Lacipil, Prelum
  • Latvia · Lacipil, Prelum
  • Malta · Lacidipine Doc Generici
  • Poland · Lacipil, Lacydyna
  • Portugal · Lacipil
  • Slovenia · Lacidipin Teva, Lacipil
  • Slovakia · Lacipil

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/562d156b-acdd-4e12-8cfa-3b67d1f105db
GET /v1/drugs/562d156b-acdd-4e12-8cfa-3b67d1f105db?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h114065_smpc.pdf",
  "strength": null,
  "atc_label": "Lacidipine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg114065",
  "excipients": [
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POVIDON K 30 (E 1201)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "LACIDIPINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h114065.pdf",
  "authorised_at": "2016/07/20",
  "procedure_number": "NL/H/2992/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "114065",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about lacidipine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console